Details

COVID-19 has a major impact on all medical disciplines, among them hepatology. The new vaccines have potential to finally solve this global health crisis. This webinar will dive into different issues related to COVID-19 vaccination including the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations (e.g. old age), the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases. The scientific rationale for currently recommended vaccination strategies concerning patients with liver diseases will also be discussed, as well as the first outcome data of population-based vaccination in patients with and without liver diseases.

Date: 09.03.2021

Time: 18:00-19:30 CET

Register now! https://us02web.zoom.us/webinar/register/WN_Bq8s6xpMQMCu3IqqJ479DA

 

Target Audience

  • Hepatologists, gastroenterologists
  • General practitioners
  • Health care professionals
  • Clinical scientists
  • Basic scientists

Learning Objectives

  • Learn about the relative risk for severe COVID-19 in patients with chronic liver diseases (cirrhosis, metabolic and autoimmune liver disease, liver transplantation) as compared to other high-risk populations
  • Learn about the efficacy and safety of current COVID-19 vaccines (mRNA vaccines, vector vaccines), their contraindications and limitations in patients with liver diseases
  • Learn about the scientific rationale for currently recommended vaccination strategies concerning patients with liver diseases
  • Learn about the first outcome data of population-based vaccination in patients with and without liver diseases

 

Programme

Time Title
18:00-18:02

Welcome & Introduction

Ulrich Spengler, University of Bonn, Germany

Verena Keitel, University Hospital of Düsseldorf, Germany

18:02-18:17

Defining liver patients in urgent need of a COVID-19 vaccine for priorisation

Thomas Marjot, University of Oxford, United Kingdom

18:17-18:32

Overview of the COVID-19 vaccines available in Europe

Julian Schulze-zur-Wiesch, University Medical Center Hamburg-Eppendorf, Germany

18:32-18:47

Benefit/Risk of COVID-19 vaccinations: Current knowledge and how it translates to specific populations

Miriam Sturkenboom, Julius Center Research Program Cardiovascular Epidemiology, Netherlands

18:47-19:02

First practical experiences with COVID-19 vaccination in Israeli patients with liver disease

Rifaat Safadi, Hadassah Medical Centers of the Hebrew, University Jerusalem, Israel

 19:02-19:30

Discussion and Q&A

All

UEMS

 

 

 

 

EASL applied for CME accreditation of this webinar. More information on CME credits will be available soon.